一般演題（口演）47 KRAS遺伝子変異陽性肺癌

[O47-3] Pan-tumor activity of olomorasib, a KRAS G12Ci, in KRAS G12C-mutant advanced solid tumors

^○Yutaka Fujiwara¹, Rebecca S. Heist², Takafumi Koyama³, Yonina R. Murciano-Goroff⁴, Antoine Hollebecque⁵, Philippe Cassier⁶, Ji-Youn Han⁷, Diego Tosi⁸, Adrian Sacher⁹, Timothy F. Burns¹⁰, Alexander I. Spira¹¹, Carlos-Alberto Gomez-Roca¹², Toshio Shimizu¹³, Natraj Reddy Ammakkanavar¹⁴, Joshua K. Sabari¹⁵, Misako Nagasaka¹⁶, Aaron Fink¹⁷, Aaron Chen¹⁷, Melinda D. Willard¹⁷, Geoffrey R. Oxnard¹⁷, Yasutoshi Kuboki¹⁸ (1.Aichi Cancer Center Hospital, Aichi, Japan, 2.Massachusetts General Hospital, Boston, MA, USA, 3.Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, 4.Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5.Gustave Roussy, Villejuif, France, 6.Department of Medical Oncology, Centre Léon Bérard, Lyon, France, 7.Research Institute, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea, 8.Institut régional du Cancer de Montpellier（ICM）, Montpellier, France, 9.Department of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada, 10.Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA, 11.Virginia Cancer Specialists, Fairfax, VA, USA, 12.Institut Universitaire du Cancer de Toulouse（IUCT）-Oncopole, Toulose, France, 13.Wakayama Medical University Hospital, Wakayama, Japan, 14.Community Health Network, Indianapolis, IN, USA, 15.NYU Langone Health - Perlmutter ＆ Long Island, New York, NY, USA, 16.University of California Irvine School of Medicine, Orange, CA, USA, 17.Loxo@Lilly, Stamford, CT, USA, 18.Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan)

アンコール演題